Balance

Getting started

Getting started

Getting started on Waylivra

Start Waylivra in conjunction with a strict low-fat diet in patients with genetically confirmed FCS for whom response to diet and triglyceride lowering therapy has been inadequate1

Waylivra is a once-weekly, self-administered injection delivered in a single-use prefilled syringe1

Waylivra

Waylivra injection guide

Watch a video about how to inject Waylivra.

Dosing frequency should be adjusted based on your patients’ response to treatment1

It is important to maintain the FCS-specific low-fat diet together with Waylivra, for effective TG control1

Platelet monitoring is necessary during treatment with Waylivra1

  • In the APPROACH trial, confirmed reductions in platelet counts to below normal (140 × 109/L) were observed in 75% of patients treated with Waylivra and 24% of those on placebo1
  • Prior to initiation of Waylivra, patients should have a platelet count ≥140 × 109/L1
  • During treatment, platelet levels should be monitored at least every 2 weeks and dosing and frequency of montioring modified accordingly1

Diet is an integral part of the management of FCS2

It is critical for your patients to understand that Waylivra must be used in conjunction with a severely restricted low-fat diet, including avoidance of alcohol1

*Inadequate response defined as a reduction in serum triglycerides <25% or failure to achieve serum triglycerides <22.6 mmol/L after 3 months on Waylivra 285 mg weekly.1

**Provided platelet counts are normal

a Discontinuation of antiplatelet medicinal products/NSAIDs/anticoagulants should be considered for platelet levels <75 × 109/L. Treatment with these medicinal products must be discontinued at platelet levels <50 × 109/L.1

b Consultation of a haematologist is needed to reconsider the benefit/risk for possible further treatment with Waylivra in a patient who has discontinued due to severe thrombocyotpenia (<50 x 109/L).1

References

  1. Waylivra® SmPC
  2. Williams L, et al. J Clin Lipidol. 2018;12(4):908–919.